Retinoblastoma
101
16
25
40
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.9%
13 terminated out of 101 trials
75.5%
-11.1% vs benchmark
9%
9 trials in Phase 3/4
23%
9 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (101)
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Early Check: Expanded Screening in Newborns
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
Familial Investigations of Childhood Cancer Predisposition
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Retinoblastoma Phase II Expanded Access Clinical Trial
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Retinoblastoma Patient Clinical Database and Tissue Repository
Retinoblastoma Consolidation in Egyptians
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
Conservative Treatments of Retinoblastoma
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults